Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Avata Biosciences General Information
SAP021 demonstrated favorable safety/tolerability and pharmacokinetics compared to Epidiolex® in a two-part Phase I trial. The company is pursuing expedited FDA review via the de-risked US regulatory pathway with commercial launch targeted post-FDA approval (~2028).
Contact Information
Website
Primary Industry
Biotech
Corporate Office
London, England
United Kingdom
United Kingdom
Drug Pipeline
AVAT-021
Phase 1Key Partnerships
Oxford University – partnership focused on mental health indications using their lead program.
Avata Biosciences Funding
No funding data available
To view Avata Biosciences's complete valuation and funding history, request access »